NCT06960213Phase 3Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Study sponsor: ADARx Pharmaceuticals, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-11-30Estimated

Enrollment · participants90Estimated

Source updated2026-09-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-10 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2027-06-30

+ Updated value

2027-11-30

Check registry source

Posted 2026-01-22 · 2 fields changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Efficacy of ADX-324 in preventing investigator-confirmed HAE attacks

+ Updated value

measure: Efficacy of ADX-324 in preventing HAE attacks

The saved outcome text may be shortened. Check the source for full wording.

Primary completion date

Recorded edit

− Previous value

2026-12-31

+ Updated value

2027-06-30

Check registry source